164 related articles for article (PubMed ID: 37764221)
1. The Protective Effects of Water-Soluble Alginic Acid on the N-Terminal of Thymopentin.
Ji H; Fan Y; Gao X; Gong Y; Dai K; Wang Z; Xu B; Yu J
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764221
[TBL] [Abstract][Full Text] [Related]
2. Thymopentin ameliorates dextran sulfate sodium-induced colitis by triggering the production of IL-22 in both innate and adaptive lymphocytes.
Cao Q; Gao X; Lin Y; Yue C; Wang Y; Quan F; Zhang Z; Liu X; Lu Y; Zhan Y; Yang H; Li X; Qin D; Birnbaumer L; Hao K; Yang Y
Theranostics; 2019; 9(25):7490-7505. PubMed ID: 31695782
[No Abstract] [Full Text] [Related]
3. The immunosuppressive effects of low molecular weight chitosan on thymopentin-activated mice bearing H22 solid tumors.
Ji HY; Liu C; Dai KY; Yu J; Liu AJ; Chen YF
Int Immunopharmacol; 2021 Oct; 99():108008. PubMed ID: 34330058
[TBL] [Abstract][Full Text] [Related]
4. Targeting the TLR2 Receptor With a Novel Thymopentin-Derived Peptide Modulates Immune Responses.
Wei X; Zhang L; Zhang R; Wu R; Petitte JN; Hou Y; Si D; Ahmad B; Guo H; Zhang M; Cheng Q; Tong Y
Front Immunol; 2021; 12():620494. PubMed ID: 34122400
[TBL] [Abstract][Full Text] [Related]
5. TP5 triggers signal transduction involving mitogen activated protein kinases in monocytes.
Gonser S; Crompton NE; Weber PJ; Beck-Sickinger AG; Folkers G
J Recept Signal Transduct Res; 1999; 19(1-4):155-66. PubMed ID: 10071755
[TBL] [Abstract][Full Text] [Related]
6. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.
Li J; Cheng Y; Zhang X; Zheng L; Han Z; Li P; Xiao Y; Zhang Q; Wang F
Cancer Lett; 2013 Sep; 337(2):237-47. PubMed ID: 23684552
[TBL] [Abstract][Full Text] [Related]
7. Myristic acid-modified thymopentin for enhanced plasma stability and immune-modulating activity.
Tan Y; Wang W; Wu C; Pan Z; Yao G; Fang L; Su W
Int Immunopharmacol; 2017 Jun; 47():88-94. PubMed ID: 28365509
[TBL] [Abstract][Full Text] [Related]
8. Modulation of IL-2, IFN-gamma, TNF-alpha and IL-4 production in mice of different ages by thymopentin.
Cillari E; Milano S; Perego R; Gromo G; D'Agostino R; Arcoleo F; Dieli M
Int J Immunopharmacol; 1992 Aug; 14(6):1029-35. PubMed ID: 1428357
[TBL] [Abstract][Full Text] [Related]
9. Thymopentin (TP5), an immunomodulatory peptide, suppresses proliferation and induces differentiation in HL-60 cells.
Fan YZ; Chang H; Yu Y; Liu J; Zhao L; Yang DJ; Wang R
Biochim Biophys Acta; 2006 Oct; 1763(10):1059-66. PubMed ID: 16952408
[TBL] [Abstract][Full Text] [Related]
10. [Mediation of cellular immune response by TP5 in pathogenesis of myasthenia gravis].
He XT; Liu WB; Zhang Y; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(47):3337-40. PubMed ID: 20193562
[TBL] [Abstract][Full Text] [Related]
11. Peptides and polypeptides as modulators of the immune response: thymopentin--an example with unknown mode of action.
Gonser S; Weber E; Folkers G
Pharm Acta Helv; 1999 Jun; 73(6):265-73. PubMed ID: 10443171
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory activity of a potent thymopentin analog: disulphide bridged beta-mercaptopropionyl-arginyl-lysyl-aspartyl-valyl-tyrosyl-cysteine amide.
Wieczorek Z; Zimecki M; Trojnar J; Siemion IZ
Pol J Pharmacol; 1996; 48(1):31-8. PubMed ID: 9112625
[TBL] [Abstract][Full Text] [Related]
13. Increased antitumor activity of tumor-specific peptide modified thymopentin.
Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
[TBL] [Abstract][Full Text] [Related]
14. Intein-mediated expression, purification, and characterization of thymosin α1-thymopentin fusion peptide in Escherichia coli.
Li J; Zheng L; Li P; Wang F
Protein Expr Purif; 2012 Jul; 84(1):1-8. PubMed ID: 22554820
[TBL] [Abstract][Full Text] [Related]
15. Increased radiation toxicity by enhanced apoptotic clearance of HL-60 cells in the presence of the pentapeptide thymopentin, which selectively binds to apoptotic cells.
Gonser S; Crompton NE; Folkers G; Weber E
Mutat Res; 2004 Mar; 558(1-2):19-26. PubMed ID: 15036115
[TBL] [Abstract][Full Text] [Related]
16. Research on thymopentin loaded oral N-trimethyl chitosan nanoparticles.
Yuan XJ; Zhang ZR; Song QG; He Q
Arch Pharm Res; 2006 Sep; 29(9):795-9. PubMed ID: 17024854
[TBL] [Abstract][Full Text] [Related]
17. Vesicular phospholipid gels using low concentrations of phospholipids for the sustained release of thymopentin: pharmacokinetics and pharmacodynamics.
Zhong Y; Chen L; Zhang Y; Li W; Sun X; Gong T; Zhang Z
Pharmazie; 2013 Oct; 68(10):811-5. PubMed ID: 24273885
[TBL] [Abstract][Full Text] [Related]
18. Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies.
Zhang T; Qin XY; Cao X; Li WH; Gong T; Zhang ZR
Acta Pharmacol Sin; 2019 Apr; 40(4):514-521. PubMed ID: 30002492
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of thymopentin binding to HLA-DR molecules.
Liu Z; Zheng X; Wang J; Wang E
PLoS One; 2007 Dec; 2(12):e1348. PubMed ID: 18159232
[TBL] [Abstract][Full Text] [Related]
20. Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization.
Gao D; Zhang X; Zhang J; Cao J; Wang F
Arch Pharm Res; 2008 Nov; 31(11):1471-6. PubMed ID: 19023544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
